ClinicalTrials.gg
CompletedNCT00159861Updated Feb 1, 2021Results posted

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

A Phase 3 interventional study of Sildenafil citrate in Pulmonary Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 52 sites in 11 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.

Enrollment
3rd of 50
267 · median 30
Started
2003
with 2 others
Phase 3
15 of 51
none open now
Registered
3rd of 51
by date
Lead sponsor
7 of 51
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 3rd largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2003, is one of 15 in phase 3, and was the 3rd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing sildenafil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension

03

Conditions studied

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion

Exclusion criteria

Exclusion Criteria:

  • PH other than PAH
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
267 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Categorized Change From Baseline in 6-Minute Walking Distance

    Number of subjects with categorized change in 6-minute walking distance. Distance that a subject could walk in 6-minutes at a comfortable pace with as many breaks as needed. Performed as close to trough levels of sildenafil as possible (just before dosing; at least 4 hours after the previous dose of study drug). Scores for categorized changes for missing visits were imputed as the worse score of its non-missing neighbors. If a visit was missing and there was no subsequent score, the score was coded to missing.

    Time frame: 1 Year, 2 Year, 3 Year

Secondary outcomes

  1. Survival Status

    Yearly survival status: number of subjects who survived, discontinued, and died. Analysis includes post-treatment visit data from subjects who discontinued study treatment. Time to death was taken relative to the first dose of study treatment in A1481141, and was censored on the last day the subject was known to be alive in A1481141 or A1481153.

    Time frame: 1, 2, 3, 4, and 5 years

  2. Change in Pulmonary Hypertension Criteria for Functional Capacity and Therapeutic Class

    Pulmonary hypertension (PH) criteria: Class I: PH without limitation of physical activity (PA) (no undue dyspnea, fatigue, chest pain, near syncope); Class II: PH with slight limitation in PA, comfortable at rest, ordinary PA causes undue dyspnea, fatigue, chest pain, near syncope; Class III: PH with marked limitation in PA, comfortable at rest, less than ordinary activity causes undue dyspnea, fatigue, chest pain or syncope; Class IV: PH with inability to carry out PA without symptoms, signs of right heart failure, dyspnea or fatigue may be present at rest, discomfort increased by any PA.

    Time frame: 1 Year, 2 Year, 3 Year

  3. Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)

    Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Change from baseline = score at observation minus score at baseline.

    Time frame: Baseline, Month 15, Month 27, Month 39

  4. Change From Baseline in European Quality of Life Scale (EuroQol) 5-Dimensions (EQ-5D): Utility Index Score

    EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline, Month 15, Month 27, Month 39

  5. Change From Baseline in European Quality of Life (EuroQol) Visual Analogue Scale (EQ-5D VAS): Current Health State Score

    EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline, Month 15, Month 27, Month 39

  6. Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36): Reported Health Transition Score

    Subject-rated measure of health status (36 items): 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health), 2 summary scores (physical component, mental component), and a self-evaluated change in health status. Change from Baseline in SF-36 Health Transition score at each visit. I=much better than 1 year ago; II=somewhat better than 1 year ago; III=about the same as 1 year ago; IV=somewhat worse than 1 year ago; V=much worse than 1 year ago

    Time frame: Baseline, Month 15, Month 27, Month 39

  7. Change From Baseline in BORG Dyspnea Score

    BORG Dyspnea score: change from core study Baseline. Subject rating of maximum degree of dyspnea experienced at any time during the 6-Minute Walk Test. Range: 0 (no breathlessness at all) to 10 (maximum breathlessness).

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36

Other outcomes

  1. Change in Epoprostenol Dose From Baseline Maintained for 6 Months

    Number of subjects with changes in Epoprostenol dose from baseline maintained continuously for 6 months. Increased = Epoprostenol dose continuously more than 20% greater than core study Baseline for at least 6 months. Decrease = Epoprostenol dose continuously more than 20% less than core study Baseline for at least 6 months. No change = Epoprostenol dose change met neither Increase or Decrease criteria. Stopped = Epoprostenol dose stopped for at least 6 months.

    Time frame: Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, and at 3-month intervals through Month 69

07

Results

Posted Jan 12, 2011

Participant flow

Core Study - 16 Weeks
Participant flow — Core Study - 16 Weeks
MilestonePlacebo: Core Study / Sildenafil: Extension StudySildenafil: Core Study / Sildenafil: Extension Study
Started133134
Treated131134
Completed108122
Not completed2512
Withdrew: Death30
Withdrew: Adverse event126
Withdrew: Lack of efficacy23
Withdrew: Reason unspecified53
Withdrew: Subject defaulted10
Withdrew: Randomized but not treated20
Extension Study - up to 3 Years
Participant flow — Extension Study - up to 3 Years
MilestonePlacebo: Core Study / Sildenafil: Extension StudySildenafil: Core Study / Sildenafil: Extension Study
Started115127
Treated115127
Completed5356
Not completed6271
Withdrew: Death2428
Withdrew: Adverse event1414
Withdrew: Lack of efficacy51
Withdrew: Reason unspecified1219
Withdrew: Withdrawal by subject79

Outcome measures

Other pre-specifiedChange in Epoprostenol Dose From Baseline Maintained for 6 Months

Number of subjects with changes in Epoprostenol dose from baseline maintained continuously for 6 months. Increased = Epoprostenol dose continuously more than 20% greater than core study Baseline for at least 6 months. Decrease = Epoprostenol dose continuously more than 20% less than core study Baseline for at least 6 months. No change = Epoprostenol dose change met neither Increase or Decrease criteria. Stopped = Epoprostenol dose stopped for at least 6 months.

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, and at 3-month intervals through Month 69
Reported as:
Number · participants
Change in Epoprostenol Dose From Baseline Maintained for 6 Months
participantsAll Subjects
Week 4: >20% Increase0
Week 4: No Change0
Week 4: >20% Decrease0
Week 4: Stopped0
Week 4: Missing13
Week 8: >20% Increase0
Week 8: No Change0
Week 8: >20% Decrease0
Week 8: Stopped0
Week 8: Missing11
Week 12: >20% Increase0
Week 12: No Change0
Week 12: >20% Decrease0
Week 12: Stopped0
Week 12: Missing14
Week 16: >20% Increase0
Week 16: No Change0
Week 16: >20% Decrease0
Week 16: Stopped0
Week 16: Missing199
Week 20: >20% Increase0
Week 20: No Change0
Week 20: >20% Decrease0
Week 20: Stopped0
Week 20: Missing186
Week 24: >20% Increase0
Week 24: No Change0
Week 24: >20% Decrease0
Week 24: Stopped0
Week 24: Missing190
Month 9: >20% Increase0
Month 9: No Change0
Month 9: >20% Decrease0
Month 9: Stopped0
Month 9: Missing174
Month 12: >20% Increase4
Month 12: No Change162
Month 12: >20% Decrease9
Month 12: Stopped0
Month 12: Missing0
Month 15: >20% Increase5
Month 15: No Change130
Month 15: >20% Decrease20
Month 15: Stopped1
Month 15: Missing0
Month 18: >20% Increase10
Month 18: No Change109
Month 18: >20% Decrease27
Month 18: Stopped1
Month 18: Missing0
Month 21: >20% Increase10
Month 21: No Change105
Month 21: >20% Decrease27
Month 21: Stopped2
Month 21: Missing0
Month 24: >20% Increase15
Month 24: No Change93
Month 24: >20% Decrease24
Month 24: Stopped2
Month 24: Missing0
Month 27: >20% Increase18
Month 27: No Change87
Month 27: >20% Decrease23
Month 27: Stopped3
Month 27: Missing0
Month 30: >20% Increase19
Month 30: No Change78
Month 30: >20% Decrease23
Month 30: Stopped3
Month 30: Missing0
Month 33: >20% Increase18
Month 33: No Change76
Month 33: >20% Decrease22
Month 33: Stopped2
Month 33: Missing0
Month 36: >20% Increase20
Month 36: No Change66
Month 36: >20% Decrease19
Month 36: Stopped4
Month 36: Missing0
Month 39: >20% Increase19
Month 39: No Change55
Month 39: >20% Decrease19
Month 39: Stopped5
Month 39: Missing0
Month 42: >20% Increase19
Month 42: No Change55
Month 42: >20% Decrease18
Month 42: Stopped5
Month 42: Missing0
Month 45: >20% Increase24
Month 45: No Change51
Month 45: >20% Decrease15
Month 45: Stopped4
Month 45: Missing0
Month 48: >20% Increase23
Month 48: No Change38
Month 48: >20% Decrease17
Month 48: Stopped5
Month 48: Missing0
Month 51: >20% Increase17
Month 51: No Change33
Month 51: >20% Decrease14
Month 51: Stopped3
Month 51: Missing0
Month 54: >20% Increase14
Month 54: No Change31
Month 54: >20% Decrease14
Month 54: Stopped5
Month 54: Missing0
Month 57: >20% Increase12
Month 57: No Change27
Month 57: >20% Decrease12
Month 57: Stopped4
Month 57: Missing0
Month 60: >20% Increase12
Month 60: No Change22
Month 60: >20% Decrease11
Month 60: Stopped2
Month 60: Missing0
Month 63: >20% Increase6
Month 63: No Change21
Month 63: >20% Decrease4
Month 63: Stopped1
Month 63: Missing0
Month 66: >20% Increase4
Month 66: No Change15
Month 66: >20% Decrease2
Month 66: Stopped1
Month 66: Missing0
Month 69: >20% Increase4
Month 69: No Change9
Month 69: >20% Decrease1
Month 69: Stopped0
Month 69: Missing0
SecondarySurvival Status

Yearly survival status: number of subjects who survived, discontinued, and died. Analysis includes post-treatment visit data from subjects who discontinued study treatment. Time to death was taken relative to the first dose of study treatment in A1481141, and was censored on the last day the subject was known to be alive in A1481141 or A1481153.

Time frame:
1, 2, 3, 4, and 5 years
Reported as:
Number · participants
Survival Status
participantsAll Subjects
1 year: Deaths24
1 Year: Survived 1 Year of Study205
1 Year: Discontinued before 1 Year of Study36
2 Years: Deaths48
2 Years: Survived 2 Years of Study169
2 Years: Discontinued before 2 Years of Study48
3 Years: Deaths64
3 Years: Survived 3 Years of Study133
3 Years: Discontinued before 3 Years of Study68
4 Years: Deaths71
4 Years: Survived 4 Years of Study88
4 Years: Discontinued before 4 Years of Study75
4 Years: Ongoing for Less than Timepoint26
5 Years: Deaths82
5 Years: Survived 5 Years of Study29
5 Years: Discontinued before 5 Years of Study74
5 Years: Ongoing for Less than Timepoint78
Statistical analysis
  • All Subjects · Kaplan-meier estimate: 0.095 · 95% CI 0.059 to 0.132
  • All Subjects · Kaplan-meier estimate: 0.194 · 95% CI 0.144 to 0.243
  • All Subjects · Kaplan-meier estimate: 0.260 · 95% CI 0.205 to 0.315
  • All Subjects · Kaplan-meier estimate: 0.291 · 95% CI 0.234 to 0.348
  • All Subjects · Kaplan-meier estimate: 0.369 · 95% CI 0.302 to 0.437
PrimaryCategorized Change From Baseline in 6-Minute Walking Distance

Number of subjects with categorized change in 6-minute walking distance. Distance that a subject could walk in 6-minutes at a comfortable pace with as many breaks as needed. Performed as close to trough levels of sildenafil as possible (just before dosing; at least 4 hours after the previous dose of study drug). Scores for categorized changes for missing visits were imputed as the worse score of its non-missing neighbors. If a visit was missing and there was no subsequent score, the score was coded to missing.

Time frame:
1 Year, 2 Year, 3 Year
Reported as:
Number · participants
Categorized Change From Baseline in 6-Minute Walking Distance
participantsPlacebo/SildenafilSildenafil/Sildenafil
1 Year: >= 60 m Improvement2746
1 Year: 60 - 30 m Improvement2026
1 Year: 30 - 0 m Improvement2315
1 Year: 0 - 30 m Worsening1210
1 Year: 30 - 60 m Worsening66
1 Year: > 60 m Worsening66
1 Year: Discontinued2214
1 Year: Died1410
1 Year: Missing11
2 Year: >= 60 m Improvement2344
2 Year: 60 - 30 m Improvement1610
2 Year: 30 - 0 m Improvement158
2 Year: 0 - 30 m Worsening189
2 Year: 30 - 60 m Worsening27
2 Year: > 60 m Worsening77
2 Year: Discontinued2523
2 Year: Died2424
2 Year: Missing12
3 Year: >= 60 m Improvement2229
3 Year: 60 - 30 m Improvement910
3 Year: 30 - 0 m Improvement108
3 Year: 0 - 30 m Worsening155
3 Year: 30 - 60 m Worsening37
3 Year: > 60 m Worsening58
3 Year: Discontinued3533
3 Year: Died3133
3 Year: Missing11
SecondaryChange in Pulmonary Hypertension Criteria for Functional Capacity and Therapeutic Class

Pulmonary hypertension (PH) criteria: Class I: PH without limitation of physical activity (PA) (no undue dyspnea, fatigue, chest pain, near syncope); Class II: PH with slight limitation in PA, comfortable at rest, ordinary PA causes undue dyspnea, fatigue, chest pain, near syncope; Class III: PH with marked limitation in PA, comfortable at rest, less than ordinary activity causes undue dyspnea, fatigue, chest pain or syncope; Class IV: PH with inability to carry out PA without symptoms, signs of right heart failure, dyspnea or fatigue may be present at rest, discomfort increased by any PA.

Time frame:
1 Year, 2 Year, 3 Year
Reported as:
Number · participants
Change in Pulmonary Hypertension Criteria for Functional Capacity and Therapeutic Class
participantsPlacebo/SildenafilSildenafil/Sildenafil
1 Year: Improved 2 Classes23
1 Year: Improved 1 Class2746
1 Year: No Change5957
1 Year: Worsened 1 Class73
1 Year: Worsened 2 Classes01
1 Year: Discontinued2214
1 Year: Died1410
2 Year: Improved 2 Classes14
2 Year: Improved 1 Class2431
2 Year: No Change5047
2 Year: Worsened 1 Class75
2 Year: Worsened 2 Classes00
2 Year: Discontinued2523
2 Year: Died2424
3 Year: Improved 2 Classes14
3 Year: Improved 1 Class2121
3 Year: No Change3937
3 Year: Worsened 1 Class36
3 Year: Worsened 2 Classes10
3 Year: Discontinued3533
3 Year: Died3133
SecondaryChange From Baseline in Medical Outcomes Study Short Form 36 (SF-36)

Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health), 2 summary scores (physical component and mental component), and a self-evaluated change in health status. Subscale and summary scores range: 0-100. Higher subscale and summary scores = better health status. Change from baseline = score at observation minus score at baseline.

Time frame:
Baseline, Month 15, Month 27, Month 39
Reported as:
Mean · scores on scale
Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36)
scores on scalePlacebo/SildenafilSildenafil/Sildenafil
Month 15: Physical Functioning Score (n=59, 83)10.5 (6.0 to 15.1)14.8 (10.1 to 19.4)
Month 27: Physical Functioning Score (n=60, 62)9.7 (5.0 to 14.4)12.5 (7.1 to 17.9)
Month 39: Physical Functioning Score (n=42, 47)8.9 (1.9 to 15.9)14.0 (7.6 to 20.4)
Month 15: Role Limitations (phys health)(n=59, 82)15.7 (4.9 to 26.4)14.2 (3.3 to 25.2)
Month 27: Role Limitations (phys health)(n=60, 62)4.6 (-8.3 to 17.5)2.6 (-9.8 to 14.9)
Month 39: Role Limitations (phys health)(n=42, 47)4.2 (-11.0 to 19.4)5.1 (-9.8 to 20.1)
Month 15: Bodily Pain Score (n=59, 82)10.4 (4.5 to 16.3)5.9 (0.3 to 11.5)
Month 27: Bodily Pain Score (n=60, 62)-0.1 (-6.4 to 6.3)4.0 (-1.8 to 9.9)
Month 39: Bodily Pain Score (n=42, 46)-4.9 (-13.2 to 3.4)3.5 (-3.4 to 10.5)
Month 15: General Health Score (n=59, 83)-0.2 (-5.5 to 5.2)10.1 (5.4 to 14.7)
Month 27: General Health Score (n=60, 62)2.7 (-2.6 to 8.1)6.9 (2.0 to 11.7)
Month 39: General Health Score (n=41, 47)3.1 (-2.6 to 8.7)3.4 (-2.8 to 9.7)
Month 15: Vitality Score (n=59, 83)5.0 (-0.3 to 10.4)8.9 (3.7 to 14.0)
Month 27: Vitality Score (n=60, 62)5.7 (0.8 to 10.5)7.2 (2.0 to 12.3)
Month 39: Vitality Score (n=42, 47)6.9 (0.3 to 13.6)5.2 (-0.7 to 11.1)
Month 15: Social Functioning Score (n=59, 83)5.9 (-2.2 to 14.1)5.1 (-1.2 to 11.5)
Month 27: Social Functioning Score (n=60, 63)6.7 (-0.6 to 13.9)1.4 (-6.5 to 9.3)
Month 39: Social Functioning Score (n=42, 47)2.4 (-5.9 to 10.6)-0.8 (-9.3 to 7.7)
Month 15: Role Limitations (Emotional) (n=59, 82)1.7 (-10.1 to 13.5)1.2 (-8.8 to 11.3)
Month 27: Role Limitations (Emotional) (n=60, 62)-1.7 (-13.4 to 10.0)-7.0 (-18.1 to 4.1)
Month 39: Role Limitations (Emotional) (n=42, 47)3.2 (-10.7 to 17.1)2.1 (-7.5 to 11.8)
Month 15: Mental Health Score (n=59, 83)0.5 (-3.9 to 4.9)3.3 (-1.1 to 7.7)
Month 27: Mental Health Score (n=60, 62)0.9 (-3.4 to 5.1)0.1 (-4.6 to 4.8)
Month 39: Mental Health Score (n=42, 47)0.8 (-4.9 to 6.6)3.7 (-1.9 to 9.3)
SecondaryChange From Baseline in European Quality of Life Scale (EuroQol) 5-Dimensions (EQ-5D): Utility Index Score

EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline, Month 15, Month 27, Month 39
Reported as:
Mean · scores on scale
Change From Baseline in European Quality of Life Scale (EuroQol) 5-Dimensions (EQ-5D): Utility Index Score
scores on scalePlacebo/SildenafilSildenafil/Sildenafil
Month 15 (n=58, 78)0.0505 (-0.0078 to 0.1087)0.0473 (-0.0065 to 0.1012)
Month 27 (n=56, 60)0.0489 (-0.0146 to 0.1123)0.0483 (-0.0272 to 0.1237)
Month 39 (n=40, 43)-0.0278 (-0.1253 to 0.0697)0.0770 (0.0013 to 0.1526)
SecondaryChange From Baseline in European Quality of Life (EuroQol) Visual Analogue Scale (EQ-5D VAS): Current Health State Score

EQ-5D: subject rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline, Month 15, Month 27, Month 39
Reported as:
Mean · scores on scale
Change From Baseline in European Quality of Life (EuroQol) Visual Analogue Scale (EQ-5D VAS): Current Health State Score
scores on scalePlacebo/SildenafilSildenafil/Sildenafil
Month 15 (n=57, 81)6.8 (2.4 to 11.1)12.8 (8.3 to 17.3)
Month 27 (n=55, 60)5.5 (1.7 to 9.3)11.2 (5.9 to 16.4)
Month 39 (n=40, 41)4.7 (-0.2 to 9.5)11.5 (5.5 to 17.5)
SecondaryChange From Baseline in Medical Outcomes Study Short Form 36 (SF-36): Reported Health Transition Score

Subject-rated measure of health status (36 items): 8 subscale scores (physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, mental health), 2 summary scores (physical component, mental component), and a self-evaluated change in health status. Change from Baseline in SF-36 Health Transition score at each visit. I=much better than 1 year ago; II=somewhat better than 1 year ago; III=about the same as 1 year ago; IV=somewhat worse than 1 year ago; V=much worse than 1 year ago

Time frame:
Baseline, Month 15, Month 27, Month 39
Reported as:
Number · participants
Change From Baseline in Medical Outcomes Study Short Form 36 (SF-36): Reported Health Transition Score
participantsPlacebo/SildenafilSildenafil/Sildenafil
BL I; Month 15: I29
BL I; Month 15: II54
BL I; Month 15: III52
BL I; Month 15: IV01
BL I; Month 15: V00
BL II; Month 15: I75
BL II; Month 15: II912
BL II; Month 15: III37
BL II; Month 15: IV12
BL II; Month 15: V00
BL III; Month 15: I34
BL III; Month 15: II68
BL III; Month 15: III117
BL III; Month 15: IV02
BL III; Month 15: V00
BL IV; Month 15: I25
BL IV; Month 15: II03
BL IV; Month 15: III23
BL IV; Month 15: IV14
BL IV; Month 15: V10
BL V; Month 15: I01
BL V; Month 15: II03
BL V; Month 15: III01
BL V; Month 15: IV00
BL V; Month 15: V00
Month 15: Missing Data7351
BL I; Month 27: I42
BL I; Month 27: II26
BL I; Month 27: III22
BL I; Month 27: IV30
BL I; Month 27: V00
BL II; Month 27: I43
BL II; Month 27: II97
BL II; Month 27: III87
BL II; Month 27: IV13
BL II; Month 27: V00
BL III; Month 27: I35
BL III; Month 27: II76
BL III; Month 27: III97
BL III; Month 27: IV23
BL III; Month 27: V00
BL IV; Month 27: I11
BL IV; Month 27: II13
BL IV; Month 27: III13
BL IV; Month 27: IV13
BL IV; Month 27: V00
BL V; Month 27: I01
BL V; Month 27: II00
BL V; Month 27: III01
BL V; Month 27: IV00
BL V; Month 27: V00
Month 27: Missing Data7371
BL I; Month 39: I12
BL I; Month 39: II24
BL I; Month 39: III34
BL I; Month 39: IV11
BL I; Month 39: V00
BL II; Month 39: I45
BL II; Month 39: II63
BL II; Month 39: III66
BL II; Month 39: IV31
BL II; Month 39: V00
BL III; Month 39: I23
BL III; Month 39: II33
BL III; Month 39: III86
BL III; Month 39: IV11
BL III; Month 39: V00
BL IV; Month 39: I00
BL IV; Month 39: II10
BL IV; Month 39: III02
BL IV; Month 39: IV14
BL IV; Month 39: V00
BL V; Month 39: I01
BL V; Month 39: II00
BL V; Month 39: III01
BL V; Month 39: IV00
BL V; Month 39: V00
Month 39: Missing Data8987
SecondaryChange From Baseline in BORG Dyspnea Score

BORG Dyspnea score: change from core study Baseline. Subject rating of maximum degree of dyspnea experienced at any time during the 6-Minute Walk Test. Range: 0 (no breathlessness at all) to 10 (maximum breathlessness).

Time frame:
Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24, Month 27, Month 30, Month 33, Month 36
Reported as:
Median · scores on scale
Change From Baseline in BORG Dyspnea Score
scores on scalePlacebo/SildenafilSldenafil/Sildenafil
Week 4 (n=112, 120)0.0 (-9.0 to 10.0)0.0 (-6.0 to 4.0)
Week 8 (n=106, 113)0.0 (-8.0 to 9.0)0.0 (-6.0 to 4.0)
Week 12 (n=102, 108)0.0 (-6.0 to 4.0)0.0 (-7.0 to 4.0)
Week 16 (n=95, 106)0.0 (-6.0 to 9.0)0.0 (-7.0 to 6.0)
Week 20 (n=80, 96)0.0 (-8.0 to 6.0)0.0 (-7.0 to 4.0)
Week 24 (n=91, 105)0.0 (-7.0 to 4.0)0.0 (-8.0 to 4.0)
Month 9 (n=75, 98)0.0 (-4.0 to 4.0)0.0 (-8.0 to 5.0)
Month 12 (n=72, 90)0.0 (-6.0 to 4.0)0.0 (-7.0 to 4.0)
Month 15 (n=75, 91)0.0 (-6.0 to 3.0)0.0 (-9.0 to 4.0)
Month 18 (n=67, 74)0.0 (-7.0 to 3.0)0.0 (-8.0 to 4.0)
Month 21 (n=67, 79)0.0 (-6.0 to 3.0)0.0 (-7.0 to 4.0)
Month 24 (n=68, 60)0.0 (-6.0 to 7.0)0.0 (-7.0 to 5.0)
Month 27 (n=67, 69)0.0 (-4.0 to 4.0)0.0 (-7.0 to 3.0)
Month 30 (n=55, 68)0.0 (-7.0 to 7.0)0.0 (-8.0 to 5.0)
Month 33 (n=62, 65)0.0 (-4.0 to 7.0)0.0 (-7.0 to 6.0)
Month 36 (n=51, 62)0.0 (-7.0 to 5.0)0.0 (-7.0 to 5.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Sildenafil—93/115 (80.9%)115/115 (100%)
Sildenafil/Sildenafil—104/134 (77.6%)134/134 (100%)
Placebo/Discontinued—7/16 (43.8%)15/16 (93.8%)
Most frequent serious events
Showing 10 of 259
Most frequent serious events
EventPlacebo/SildenafilSildenafil/SildenafilPlacebo/Discontinued
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders15/11522/1342/16
Right ventricular failureCardiac disorders16/11513/1342/16
Catheter related infectionInfections and infestations15/11517/1340/16
Catheter related complicationGeneral disorders14/1153/1340/16
DyspnoeaRespiratory, thoracic and mediastinal disorders11/11514/1341/16
Central line infectionInfections and infestations8/11513/1340/16
PneumoniaInfections and infestations11/11512/1340/16
AnaemiaBlood and lymphatic system disorders9/1152/1340/16
Chest painGeneral disorders9/1153/1340/16
SepsisInfections and infestations9/1156/1340/16
Most frequent other events
Showing 10 of 882
Most frequent other events
EventPlacebo/SildenafilSildenafil/SildenafilPlacebo/Discontinued
HeadacheNervous system disorders75/11591/1343/16
DiarrhoeaGastrointestinal disorders54/11564/1345/16
NauseaGastrointestinal disorders48/11563/1344/16
DyspnoeaRespiratory, thoracic and mediastinal disorders44/11562/1342/16
DizzinessNervous system disorders39/11559/1345/16
FatigueGeneral disorders44/11556/1344/16
Upper respiratory tract infectionInfections and infestations39/11554/1341/16
FlushingVascular disorders35/11545/1342/16
Oedema peripheralGeneral disorders37/11538/1341/16
CoughRespiratory, thoracic and mediastinal disorders37/11540/1340/16

Baseline characteristics

Age, Customized
Age, Customized(participants)Placebo/SildenafilSildenafil/SildenafilTotal
18 to 44 years4754101
45 to 64 years7364137
>= 65 years111627
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/SildenafilSildenafil/SildenafilTotal
Female102110212
Male292453
08

Study locations

52 sites
  • Pfizer Investigational Site
    La Jolla, California 92037, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Los Angeles, California 90073, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    Torrance, California 90502, United States
  • Pfizer Investigational Site
    Torrance, California 90509, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Denver, Colorado 80262, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70112, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21287, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02111, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02114, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Rochester, Minnesota 55905, United States
  • Pfizer Investigational Site
    Saint Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68105, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68198-2125, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45219, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45267-0769, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02903, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232-5735, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84143, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • Pfizer Investigational Site
    Milwaukee, Wisconsin 53277, United States
  • Pfizer Investigational Site
    Leuven, 3000, Belgium
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1Y 4E9, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1Y 4W7, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • Pfizer Investigational Site
    Prague 2, 128 08, Czechia
  • Pfizer Investigational Site
    Kobenhavn, 2100, Denmark
  • Pfizer Investigational Site
    Clamart Cedex, 92141, France
  • Pfizer Investigational Site
    Grenoble Cedex 09, 38043, France
  • Pfizer Investigational Site
    Vandoeuvre Les Nancy, France
  • Pfizer Investigational Site
    Petach Tikva, 49100, Israel
  • Pfizer Investigational Site
    Bologna, 40138, Italy
  • Pfizer Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • Pfizer Investigational Site
    Nieuwegein, 3435CM, Netherlands
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Papworth Everard, Cambridgeshire CB3 8RE, United Kingdom
  • Pfizer Investigational Site
    Glasgow, G11 6NT, United Kingdom
09

References and documents

Publications

  • Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost A, Engel P, Kramer MR, Serdarevic-Pehar M, Layton GR, Sitbon O, Badesch DB; PACES Study Group. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014 Jul;33(7):689-97. doi: 10.1016/j.healun.2014.02.019. Epub 2014 Feb 22. PubMed 24815795 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jul 2003
CompletionActual
Jan 2006
Results first posted
Jan 12, 2011
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00159861
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jul 2003
Completion
Jan 2006
Results posted
Jan 12, 2011
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion